PTAB Invalidates Humira Patent In Coherus Challenge

Law360, New York (May 17, 2017, 5:11 PM EDT) -- The Patent Trial and Appeal Board invalidated a key patent for AbbVie Biotechnology Ltd.’s mega-blockbuster autoimmune disease drug Humira on Tuesday, finding the patent would have been obvious at the time of the invention.

The PTAB’s decision in inter partes review is a victory for Coherus BioSciences Inc., a California biosimilars company that, according to published reports, has been looking to launch a copycat of Humira, the world’s best-selling pharmaceutical.

The patent covers a Humira dosing regimen to treat rheumatoid arthritis. Coherus argued it would have...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.